20/11/2017 EULAR Updates Rheumatoid Arthritis Treatment Guidelines for DMARDs - Print Article

Jeff Craven

March 16, 2017

EULAR Updates Rheumatoid Arthritis Treatment

Guidelines for DMARDs
Share this content:

facebook
twitter
linkedin
google
Email
Print

Members of a steering committee and task force have

updated the European League Against Rheumatism
(EULAR) recommendations for rheumatoid arthritis
management to include new guidelines on starting effective
therapy in patients early with a goal of low disease activity
or stringent remission across 3 phases of treatment,
according to recently published guidelines in the Annals of
Rheumatic Diseases.

Josef S. Smolen, MD, from the Division of Rheumatology,

Department of Medicine at the Medical University of
Vienna in Austria, and colleagues formed a steering
committee comprising 7 rheumatologists, 1 patient
representative, and 3 fellows and a task force of 50
individuals, which consisted of members from the X-ray of hip with rheumatoid arthritis.
committee as well as 3 patients, 2 health professionals, and 2 delegates of the EULAR young rheumatologists' network,
Emerging Eular NETwork (EMEUNET), to review EULAR recommendations for RA management from 2013. The groups
performed a systematic literature review of the latest information, strategies, trials of new agents, and the latest insights since
the 2013 recommendations were published.

The task force endorsed 4 overarching principles for the recommendations:

1. Treatment of patients with RA should aim for the best care and must High-Yield Data
be based on a shared decision between the patient and the
rheumatologist. Summary
2. Treatment decisions are based on disease activity and other patient
factors, such as progression of structural damage, comorbidities, and
safety issues.
3. RA incurs high individual, medical, and societal costs, all of which Shared decision-making, dening the
should be considered in its management by the treating treatment target, assessing disease
rheumatologist. activity regularly with appropriate
4. Rheumatologists are the specialists who should primarily care for instruments, and applying the
patients with RA. sequence of drugs as proposed and in
a treat-to-target strategy will
The researchers noted the second principle on treatment decisions was maximize overall outcomes in a
initially a recommendation in the 2013 guidelines but became an overarching majority of patients with RA.
principle in the new guidelines because it represented a central and self-
evident rule to any therapeutic approach that it should constitute an
overarching principle rather than a recommendation.

http://www.rheumatologyadvisor.com/eular-updates-rheumatoid-arthritis-treatment-guidelines-for-dmards/printarticle/644709/ 1/3
20/11/2017 EULAR Updates Rheumatoid Arthritis Treatment Guidelines for DMARDs - Print Article
Additionally, the EULAR steering committee and task force released 12 recommendations based on their literature review,
which was a consolidation of 14 recommendations in the 2013 guidelines. The recommendations are not ranked in order but
are listed based on the need for initial effective therapy early and to set a treatment target.

With these prerequisites in mind, different drugs or combinations of agents are recommended in the course of the
therapeutic procedures, with suggested sequential increments, taking prognostic factors and all approved agents into
account, Dr Smolen and colleagues wrote. They also mention some agents of potential future interest, even though not yet
approved by international regulatory authorities."

The EULAR steering committee and task force made the following recommendations for RA management:

1. Therapy with disease-modifying antirheumatic drugs (DMARDs) should be started as soon as the diagnosis of RA is
made.
2. Treatment should be aimed at reaching a target of sustained remission or low disease activity in every patient.
3. Monitoring should be frequent in active disease (every 1 to 3 months); if there is no improvement by at most 3 months
after the start of treatment or the target has not been reached by 6 months, therapy should be adjusted.
4. Methotrexate should be part of the rst treatment strategy.
5. In patients with a contraindication to methotrexate (or early intolerance), leunomide or sulfasalazine should be
considered as part of the (rst) treatment strategy.
6. Short-term glucocorticoids should be considered when initiating or changing conventional synthetic DMARDs
(csDMARDS) in different dose regimens and routes of administration but should be tapered as rapidly as clinically
feasible.
7. If the treatment target is not achieved with the rst csDMARD strategy, in the absence of poor prognostic factors,
other csDMARDs should be considered.
8. If the treatment target is not achieved with the rst csDMARD strategy, when poor prognostic factors are present,
addition of a biological DMARD (bDMARD) or a targeted synthetic DMARD (tsDMARD) should be considered;
current practice would be to start a bDMARD.
9. bDMARDs and tsDMARDs should be combined with a csDMARD; in patients who cannot use csDMARDs as
comedication, interleukin-6 pathway inhibitors, and tsDMARDs may have some advantages compared with other
bDMARDs.
10. If treatment with a bDMARD or tsDMARD has failed, treatment with another bDMARD or tsDMARD should be
considered; if one TNF-inhibitor therapy has failed, patients may receive another TNF-inhibitor or an agent with
another mode of action.
11. If a patient is in persistent remission after having tapered glucocorticoids, one can consider tapering bDMARDs,
especially if this treatment is combined with a csDMARD.
12. If a patient is in persistent remission, tapering the csDMARD could be considered.

Summary and Clinical Applicability

The 2016 update of the EULAR recommendations is based on the most recent evidence in the area of RA management and
on discussions by a large and broadly international Task Force. The recommendations synthesize the current thinking on
approaching RA treatment in a set of overarching principles and recommendations, Dr Smolen and colleagues wrote in their
study.

These have been informed by [systematic literature reviews] on the efcacy and safety of the drugs. The Task Force is
convinced that adhering to these recommendations, including shared decision making, dening the treatment target, assessing
disease activity regularly with appropriate instruments and applying the sequence of drugs as proposed and in a treat-to-target
strategy, will maximize the overall outcome in a vast majority of patients with RA.

Disclosures
The researchers report various nancial disclosures, available as an online supplement.

Reference
Smolen JS, Landew R, Bijlsma J, et al. EULAR recommendations for the management of rheumatoid arthritis with
synthetic and biological disease-modifying antirheumatic drugs: 2016 update [published online March 6, 2017]. Ann Rheum
Dis. 2017; doi: 10.1136/annrheumdis-2016-210715

http://www.rheumatologyadvisor.com/eular-updates-rheumatoid-arthritis-treatment-guidelines-for-dmards/printarticle/644709/ 2/3
20/11/2017 EULAR Updates Rheumatoid Arthritis Treatment Guidelines for DMARDs - Print Article

follow @RheumAdvisor

This material may not be published, broadcast, rewritten or redistributed in any form without prior authorization. Your use of
this website constitutes acceptance of Haymarket Media's Privacy Policy and Terms & Conditions

http://www.rheumatologyadvisor.com/eular-updates-rheumatoid-arthritis-treatment-guidelines-for-dmards/printarticle/644709/ 3/3